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There is little evidence to direct health systems toward providing efficient interventions 
to address medical errors, defined as an unintended act of omission or commission or 
one not executed as intended that may or may not cause harm to the patient but does 
not achieve its intended outcome. We believe that lack of guidance on what is the most 
efficient way to reduce medical errors and improve the quality of health-care limits the 
scale-up of health system improvement interventions. Challenges to economic evalua-
tion of these interventions include defining and implementing improvement interventions 
in different settings with high fidelity, capturing all of the positive and negative effects of 
the intervention, using process measures of effectiveness rather than health outcomes, 
and determining the full cost of the intervention and all economic consequences of its 
effects. However, health system improvement interventions should be treated similarly 
to individual medical interventions and undergo rigorous economic evaluation to pro-
vide actionable evidence to guide policy-makers in decisions of resource allocation for 
improvement activities among other competing demands for health-care resources.
Keywords: health system improvement, economic analysis, cost-effectiveness, medical errors
iNtrODUctiON
It is clear that medical errors carry a very high burden of disease (1) and are considered a problem 
to be addressed by the health system as much as physiological conditions, such as ischemic heart 
disease (IHD) and stroke, the two leading causes of mortality worldwide (2). Interventions, such as 
antihypertensive and antiplatelet medications, are generally established as sufficiently cost-effective 
to reduce the risk of IHD and stroke. However, there is little evidence to direct health systems 
toward providing the most efficient interventions to address medical errors (3, 4). Medical errors 
are defined as an unintended act of omission or commission or an act not executed as intended 
that may or may not cause harm to the patient but does not achieve its intended outcome (5, 6). 
This definition encompasses care that fails to meet evidence-based standards by omitting steps 
or elements of care that have been deemed to be part of accepted international practice, even if 
it does not cause direct harm to the patient. Seeing substandard care in this light – that is, as a 
medical error – is important to draw attention to the costs to the health system and to patients 
and communities of poor quality care. Economic analyses, by which we mean cost-effectiveness 
analysis, cost–benefit analysis, and cost–utility analysis, are prevalent in the biomedical literature 
for individual medical interventions (7). We propose in this paper that the same economic analysis 
used in individual medical interventions also be routinely used to determine which interventions 
at the health system level are the most efficient in addressing medical errors.
tABLe 1 | Measurement challenges and potential solutions in conducting 
economic evaluations of health system improvement interventions.
Measurement 
challenge
Potential solutions
Defining  
intervention
Empirically define intervention; use modeling, Monte 
Carlo Simulation, and sensitivity analysis to account for 
low fidelity to intervention
Defining  
effectiveness
Measure all positive and potentially negative effects 
(balancing measures) as feasible; report all effects clearly
Process measures 
versus outcomes
Use epidemiological modeling (e.g., LiST Tool) to 
convert processes to outcomes; use DALYs or QALYs 
for all outcomes
Costing the 
intervention
Collect cost data prospectively; secure agreement with 
improvement implementers to report all resources used
Economic 
consequences 
of effects
Collect primary data if possible; report assumptions 
made and account for them in modeling
2
Broughton and Marquez Economic Analysis of Health System Improvement
Frontiers in Public Health | www.frontiersin.org October 2016 | Volume 4 | Article 218
evALUAtiON OF iMPrOveMeNt 
iNterveNtiONs tO DecreAse errOrs
There are many reports of evaluations of interventions to improve 
health service delivery to decrease the incidence of errors that 
lead to adverse health events (7–9) and to increase adherence 
to evidence-based standards (10–12), including in low- and 
middle-income countries (13–15). While the number of these is 
not as high as for interventions dealing directly with individual 
patient conditions, there is now a significant body of evidence 
of the effectiveness of such interventions. However, there are far 
fewer economic analyses of these health system improvement 
interventions (HSIIs) that decrease errors and improve quality 
(16). As a result, there is little evidence to guide health delivery 
managers and policy makers on what is the most efficient way to 
reduce adverse events and improve quality (3, 16, 17).
Because HSIIs are often complex social interventions, seek-
ing to influence both provider and patient behaviors as well as 
health-care organization, economic evaluations of these interven-
tions – including cost-effectiveness, cost–utility, and cost–benefit 
analyses – can be more difficult to conduct and more complicated 
to interpret their results. In this paper, we argue that complexity 
is no excuse not to do such evaluations. Evidence-based HSIIs 
are urgently needed to best serve those who entrust their welfare 
to health service providers and the system in which they work. 
Cost-effectiveness analyses, cost-utility analyses, and other 
economic evaluations inform decision-makers on how efficient 
and therefore how worthwhile such interventions are compared 
to other uses of scarce resources.
We outline challenges to conducting economic analysis 
on HSIIs to reduce health care-associated errors and increase 
adherence to evidence-based standards and discuss ways these 
can be overcome or accommodated (Table  1). For illustration, 
we discuss a cost-effectiveness analysis of the use of uterotonics 
during the third stage of labor to reduce the risk of post-partum 
hemorrhage (PPH) in Senegal as an example of a simple, well-
defined individual medical intervention that has a single basic 
intended effect (18) in contrast to the cost-effectiveness analysis 
of a HSII to improve compliance with essential obstetric and 
newborn care (including the use of uterotonics in the third stage 
of labor) in Niger (19). The latter considers the system of delivery 
of care rather than just the administration of a specific treatment 
to a patient group. For simplicity, this paper considers empirical 
evaluations of HSIIs, but the principles apply as well to modeling 
studies based on hypothetical interventions.
DeFiNiNG tHe iNterveNtiON
Health system improvement interventions to reduce errors and 
improve health service quality often have a degree of complexity 
and adaptation to local context that individual medical inter-
ventions usually do not. There may be multiple components in 
HSIIs, such as training of health-care providers, providing job 
aids and reminders to reinforce good practice, restoring essential 
medication supply chains, improving patient record-keeping, 
supervision or coaching, and enhancing facility infrastructure 
(20), as was the case in the Niger example. As HSIIs are often 
implemented at the service delivery level, the actual activities that 
comprise the intervention may vary substantially depending on 
the context. This is in contrast with individual medical interven-
tions in which there is generally high fidelity to a single described 
intervention. In the Senegal case, the intervention consisted only 
of a standardized dose of either misoprostol or oxytocin, and the 
outcome of interest was a drop in hemoglobin level of the mother 
or a referral to a hospital for PPH.
A solution suggested for this problem is to define explicitly all 
the components of the HSII being implemented and the context 
in which they were introduced. Then, if it is useful to consider 
the same intervention in different settings or under different cir-
cumstances in the same settings, adjustments can be made in the 
expected results through the use of different scenarios in decision 
trees and well-established statistical techniques, such as Monte 
Carlo simulations and sensitivity analyses. Such modeling could 
reduce precision in the results but would provide a more objective 
basis for estimating likely benefits under different scenarios.
DeFiNiNG tHe eFFects
Assuming success, HSIIs often have more than one positive 
effect on health outcomes of those receiving care from the 
heath provider unit involved. In the Niger example, the primary 
effect was reduced maternal morbidity and mortality. However, 
improvements in obstetric care were also accompanied by 
improvements in newborn care and therefore, a likely reduc-
tion in newborn mortality and morbidity, though this was not 
captured in the study.
A solution for this problem is to consider as many of the 
positive effects as can be feasibly measured in the analysis, 
perform separate analyses on each of them, and then report 
all outcomes as a composite score. In the example, if the inter-
vention decreased the risk of newborn asphyxia and sepsis as 
well as maternal PPH, then the cost-effectiveness result could 
be reported as “for each $100 spent, there was a decrease of X1 
cases of PPH and X2 cases of neonatal asphyxia and X3 cases 
of newborn sepsis. Alternatively, it could be reported that for a 
total of $Y2 in a facility that served Z1 people, there were X4 fewer 
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cases of PPH, X5 fewer cases of neonatal asphyxia, and X6 fewer 
cases of newborn sepsis.”
Conversely, with implementation of a HSII there may be 
unintended negative consequences of the intervention. In our 
example, increased health worker attention toward improving 
delivery of essential maternal and newborn care may lead health 
workers to neglect other parts of their duties and consequently a 
deterioration in care quality for patients not receiving service for 
the focus condition.
The way to deal with this is to measure all the unintended nega-
tive consequences that are feasible to identify and include them 
in the analysis. This is standard practice in individual medical 
intervention economic evaluations – to measure the severity and 
frequency of adverse events and to include these in the analyses.
Also, when considering multiple different health outcomes, 
both positive and negative, from an HSII, it is useful to 
denominate the outcomes in burden of disease measures, such 
as disability-adjusted life years (DALYs) or quality-adjusted life 
years (QALYs). Converting different outcomes to a single unit 
also has an advantage of permitting comparisons among HSIIs 
to identify where the health system as a whole will reap the most 
benefit from investment in HSIIs.
PrOcess MeAsUres iNsteAD OF 
OUtcOMe MeAsUres
Often in HSIIs, it is more feasible and accurate to measure the 
effect of the intervention in process measures rather than patient 
health outcomes. In the Niger example, measurement of compli-
ance to evidence-based standards of care for active management 
of the third stage of labor and essential newborn care was easier 
than measuring some maternal and neonatal outcomes, especially 
when considering relatively rare outcomes such as maternal mor-
tality from PPH. This can also be the case with individual medical 
interventions. One possible solution is to measure the process 
indicators as is feasible but then use epidemiological modeling to 
relate those process measures to tangible health outcomes using 
the best available evidence of the link between the process and 
ultimate outcomes. Models, such as the Lives Saved Tool (LiST) 
(21), offer estimates for many priority facility- and community-
based health interventions. Any uncertainty around the estimate 
of the link between processes and outcomes can be reflected 
in the model again using sensitivity analysis and Monte Carlo 
simulation as indicated.
cOstiNG OF tHe iNterveNtiON
Given the lack of fidelity to the prescribed intervention that can 
occur with HSIIs, determining the intervention’s cost can be 
difficult. The most accurate method is to collect data on costs 
prospectively, being sure to record all of the resources consumed, 
including changes to health providers’ time, compared to the 
scenario in which the HSII is not implemented. However, retro-
spective reviews of accounting records can produce reasonable 
cost estimates. Assumptions often need to be made in calculat-
ing accurately the opportunity cost of applying HSIIs, and it is 
important that these assumptions be stated explicitly in the report 
of the evaluation. Organizations implementing HSIIs may also 
be protective of cost data to protect their commercial interests. 
Therefore, it can be useful for those commissioning the interven-
tion to make such reporting a requirement of conducting the 
work. The ongoing costs of maintaining the improved level of 
service often need to be estimated with imperfect information, 
and any assumptions made here should also be stated transpar-
ently in the evaluation.
cOstiNG OF eFFects
Given that HSIIs for medical error reduction often involve multi-
ple different health outcomes, determining the economic impact 
can add significantly to the complexity of data collection and 
modeling. In the Niger example, the cost from the health system 
perspective of adverse events such as mild, moderate, or severe 
PPH, mismanaged obstructed labor, retained placenta and other 
adverse outcomes were calculated based on daily hospital costs 
and average lengths of stay. Calculating the economic impact 
from the societal perspective would have involved including the 
cost to mothers and their families of additional time in hospital 
and other related expenses. In such low-income settings, second-
ary economic data may be scarce, and primary data expensive 
and difficult to collect. Assumptions on economic impact may 
be needed, and this is acceptable if reported transparently in the 
evaluation write-up.
DiscUssiON AND cONcLUsiON
Individual medical interventions often involve a single medica-
tion (or class of medications) or medical device. There is often a 
commercial interest in providing evidence of their effectiveness 
or cost-effectiveness in treating a specific medical condition. 
Many health systems, such as the UK’s National Health Service 
and Australia’s Medicare, mandate that individual medical 
interventions must undergo rigorous cost-effectiveness analyses 
before there is financial coverage for them to be used to treat 
the specific medical conditions. This is not the case for HSIIs, 
where the intervention is generally not considered a marketable 
product and there are no mandates to prove their effectiveness or 
efficiency before they are employed. Consequently, the resources 
available to thoroughly evaluate their value in improving health 
are much smaller. Yet, HSIIs do consume resources – resources 
that could be invested in other interventions to benefit patients or 
providers. We believe that the donors and national governments 
should insist on greater transparency in the resources devoted to 
reducing medical errors and substandard care.
The solution to this is for health system policy-makers to man-
date that economic analyses of HSIIs be conducted to produce 
evidence that an HSII is acceptably cost-effective or cost-saving 
before resources are expended to implement it, particularly at 
large scale. It is clear that there are multiple competing demands 
on health-care resources in all settings, and by definition this is 
especially the case in low- and middle-income settings. It could 
be viewed as ethically dubious in such settings to implement an 
HSII without examination of its economic consequences because, 
without knowing if the intervention is affordable, sustainable, 
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or acceptably efficient, information on its effectiveness alone is 
not useful. As with individual medical interventions, studies of 
HSII effectiveness are necessary but not sufficient to recommend 
implementing the intervention in a given setting.
This is not to ignore the additional difficulties of performing 
economic analyses on complex social system interventions. It 
adds to the cost and time required to evaluate the program and 
the expertise required to carry it out. However, these factors can-
not be excuses to omit such an important aspect of determining 
the applicability of the HSII. There is no place where health-care 
resources are inexhaustible and where difficult resource allocation 
decisions do not need to be made. Economic analysis of HSIIs is a 
vital part of the science of improvement that helps health systems 
advance.
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